Gastrointestinal toxicities of novel agents in cancer therapy

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 332-342

  Asnacios, Amani ^a   Naveau, Sylvie ^a,b,c   Perlemuter, Gabriel ^a,b,c  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; BUDESONIDE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; COLESTYRAMINE; DASATINIB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LOPERAMIDE; NILOTINIB; OCTREOTIDE; PACLITAXEL; PANITUMUMAB; PARACETAMOL; PLACEBO; PREDNISOLONE; RAPAMYCIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOLYTIC HEPATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEPATITIS; HEPATITIS B; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER INJURY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PANCREATITIS; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIARRHEA; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; NEOPLASMS; PHOSPHOTRANSFERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 70349210880     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70047-4     Document Type: Article

References (95)

1. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
2. Cohen M.H., Johnson J.R., Chen Y.F., et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10 (2005) 461-466
3. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
4. Hanna N., Lilenbaum R., Ansari R., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24 (2006) 5253-5258
5. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
6. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
7. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
8. Crown J.P., Burris III H.A., Boyle F., et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112 (2008) 317-325
9. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 9 (2004) 271-281
10. Dagher R., Cohen M., Williams G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8 (2002) 3034-3038
11. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama 295 (2006) 2516-2524
12. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
13. Guilhot F., Apperley J., Kim D.W., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
14. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
15. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
16. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
17. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
18. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
19. Fanucchi M.P., Fossella F.V., Belt R., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5025-5033
20. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
21. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19 (2001) 3267-3279
22. Nakagawa K., Tamura T., Negoro S., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14 (2003) 922-930
23. Shepherd F.A., Rodrigues Pereira J., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
24. Rudin C.M., Liu W., Desai A., et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26 (2008) 1119-1127
25. - transport in T84 human colonic epithelial cells. Am J Physiol 271 (1996) C914-C922
26. Uribe J.M., Keely S.J., Traynor-Kaplan A.E., et al. Phosphatidylinos-itol 3-kinase mediates the inhibitory effect of epidermal growth factor on calcium-dependent chloride secretion. J Biol Chem 271 (1996) 26588-26595
27. McCole D.F., and Barrett K.E. Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function. Acta Physiol (Oxf) 195 (2009) 149-159
28. Loriot Y., Perlemuter G., Malka D., et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5 (2008) 268-278
29. Widakowich C., de Castro Jr. G., de Azambuja E., et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12 (2007) 1443-1455
30. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
31. Thomas S.K., Fossella F.V., Liu D., et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7 (2006) 326-331
32. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
33. Fujiwara Y., Kiura K., Toyooka S., et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 52 (2006) 99-103
34. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
35. Amador M.L., Oppenheimer D., Perea S., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64 (2004) 9139-9143
36. Li J., Cusatis G., Brahmer J., et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6 (2007) 432-438
37. Cusatis G., Gregorc V., Li J., Spreafico A., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98 (2006) 1739-1742
38. Burris III H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23 (2005) 5305-5313
39. Keely S.J., and Barrett K.E. ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells. J Biol Chem 274 (1999) 33449-33454
40. Crone S.A., Negro A., Trumpp A., et al. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron 37 (2003) 29-40
41. Al-Dasooqi N., Bowen J.M., Gibson R.J., et al. Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs 27 (2009) 173-178
42. Demetri G.D., Titton R.L., Ryan D.P., et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. N Engl J Med 351 (2004) 1779-1787
43. Van Glabbeke M., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42 (2006) 2277-2285
44. Cherny N.I. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage 36 (2008) 413-423
45. Strumberg D., Awada A., Hirte H., et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. Eur J Cancer 42 (2006) 548-556
46. le Coutre P., Ottmann O.G., Giles F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111 (2008) 1834-1839
47. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
48. Dias V.C., Madsen K.L., Mulder K.E., et al. Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. Dig Dis Sci 43 (1998) 2227-2236
49. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 (2007) 3892-3901
50. Papandreou C.N., and Logothetis C.J. Bortezomib as a potential treatment for prostate cancer. Cancer Res 64 (2004) 5036-5043
51. Barbounis V., Koumakis G., Vassilomanolakis M., et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9 (2001) 258-260
52. Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer 12 (2004) 561-570
53. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
54. Elez E., Macarulla T., and Tabernero J. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. Ann Oncol 19 Suppl 7 (2008) vii146-vii152
55. Keefe D.M., and Gibson R.J. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 15 (2007) 483-490
56. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 (2008) 620-625
57. Cohen M.H., Williams G., Johnson J.R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8 (2002) 935-942
58. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
59. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
60. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
61. Ohyashiki K., Kuriyama Y., Nakajima A., et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16 (2002) 2160-2161
62. Lin N.U., Sarantopoulos S., Stone J.R., et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood 102 (2003) 3455-3456
63. James C., Trouette H., Marit G., et al. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 17 (2003) 978-979
64. Kikuchi S., Muroi K., Takahashi S., et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 45 (2004) 2349-2351
65. Rocca P., El Jastimi S., Troncy J., et al. [Imatinib mesylate-induced acute cytolytic hepatitis]. Gastroenterol Clin Biol 28 (2004) 918-919
66. Ayoub W.S., Geller S.A., Tran T., et al. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol 39 (2005) 75-77
67. Ikuta K., Torimoto Y., Jimbo J., et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol 82 (2005) 343-346
68. Yamazaki R., Okamoto S., Chen C.K., et al. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leuk Lymphoma 47 (2006) 1427-1430
69. Dhalluin-Venier V., Besson C., Dimet S., et al. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 18 (2006) 1235-1237
70. Ferrero D., Pogliani E.M., Rege-Cambrin G., et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematolog-ica 91 (2006) ECR27
71. Pariente A., Etcharry F., Cales V., et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 18 (2006) 785-787
72. Cross T.J., Bagot C., Portmann B., et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 81 (2006) 189-192
73. Ridruejo E., Cacchione R., Villamil A.G., et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 13 (2007) 6608-6611
74. Fuster F., Medina L., Vallansot R., et al. [Imatinib-induced toxic hepatitis: description of two cases and review of the literature]. Gastroenterol Hepatol 30 (2007) 525-530
75. Mindikoglu A.L., Regev A., Bejarano P.A., et al. Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci 52 (2007) 598-601
76. Kong J.H., Yoo S.H., Lee K.E., et al. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol 118 (2007) 205-208
77. Thia T.J., Tan H.H., Chuah T.H., et al. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 49 (2008) e86-e89
78. Yamazaki R., Aisa Y., Mori T., et al. Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel. Leuk Lymphoma 50 (2009) 670-672
79. Mueller E.W., Rockey M.L., and Rashkin M.C. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 28 (2008) 1066-1070
80. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
81. Seki N., Uematsu K., Shibakuki R., et al. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 24 (2006) 3213-3214 author reply 3214-5.
82. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
83. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
84. Ho C., Davis J., Anderson F., et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 23 (2005) 8531-8533
85. Ramanarayanan J., and Scarpace S.L. Acute drug induced hepatitis due to erlotinib. Jop 8 (2007) 39-43
86. Srinivasan S., Parsa V., Liu C.Y., et al. Trastuzumab-induced hepatotoxicity. Ann Pharmacother 42 (2008) 1497-1501
87. Munster P.N., Britten C.D., Mita M., et al. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res 13 (2007) 1238-1245
88. http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/sa fety_information/DHCPL/2008.html
89. Delis S., Triantopoulou C., Bakoyiannis A., et al. Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect. Dig Liver Dis 41 (2009) 72-77
90. Ribero D., Wang H., Donadon M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110 (2007) 2761-2767
91. DeLeve L.D., Shulman H.M., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-42
92. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 4983-4990
93. Chura J.C., Van Iseghem K., Downs Jr. L.S., et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107 (2007) 326-330
94. Akaza H., Tsukamoto T., Murai M., et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37 (2007) 755-762
95. Amar S., Wu K.J., and Tan W.W. Sorafenib-induced pancreatitis. Mayo Clin Proc 82 (2007) 521